5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Rhythm Pharmaceuticals (NASDAQ:RYTM), with recent ratings varying from bullish to bearish. The average 12-month price target is $50.8, reflecting a 20.95% increase from the previous target of $42. Rhythm Pharmaceuticals, a biopharmaceutical company, has shown a revenue growth of 175.7% as of December 31, 2023, but trails behind industry peers in the Health Care sector. Its net margin and ROE are below industry standards, indicating potential challenges in profitability and equity capital utilization.
April 10, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals has received mixed analyst ratings but shows a promising 20.95% increase in the average 12-month price target. Despite significant revenue growth, it faces challenges in profitability and capital utilization.
The mixed analyst ratings combined with a significant increase in the average 12-month price target suggest a cautiously optimistic outlook for RYTM. The substantial revenue growth indicates strong operational performance, but the below-industry standards in profitability and capital utilization could temper investor enthusiasm. The overall positive price target adjustment reflects analysts' belief in the company's potential despite its challenges.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100